Free Trial
NASDAQ:ONCY

Oncolytics Biotech (ONCY) Stock Price, News & Analysis

Oncolytics Biotech logo
$0.90 +0.11 (+14.41%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$0.90 +0.00 (+0.44%)
As of 07/3/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Oncolytics Biotech Stock (NASDAQ:ONCY)

Key Stats

Today's Range
$0.77
$0.96
50-Day Range
$0.33
$0.90
52-Week Range
$0.33
$1.53
Volume
1.54 million shs
Average Volume
677,893 shs
Market Capitalization
$84.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.33
Consensus Rating
Moderate Buy

Company Overview

Oncolytics Biotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

ONCY MarketRank™: 

Oncolytics Biotech scored higher than 34% of companies evaluated by MarketBeat, and ranked 727th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oncolytics Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Oncolytics Biotech has only been the subject of 2 research reports in the past 90 days.

  • Read more about Oncolytics Biotech's stock forecast and price target.
  • Earnings Growth

    Earnings for Oncolytics Biotech are expected to decrease in the coming year, from ($0.28) to ($0.30) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oncolytics Biotech is -3.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oncolytics Biotech is -3.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oncolytics Biotech has a P/B Ratio of 18.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Oncolytics Biotech's valuation and earnings.
  • Percentage of Shares Shorted

    2.77% of the float of Oncolytics Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Oncolytics Biotech has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oncolytics Biotech has recently increased by 15.49%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Oncolytics Biotech does not currently pay a dividend.

  • Dividend Growth

    Oncolytics Biotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.77% of the float of Oncolytics Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Oncolytics Biotech has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oncolytics Biotech has recently increased by 15.49%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Oncolytics Biotech has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Oncolytics Biotech this week, compared to 2 articles on an average week.
  • Search Interest

    Only 5 people have searched for ONCY on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.10% of the stock of Oncolytics Biotech is held by insiders.

  • Percentage Held by Institutions

    Only 6.82% of the stock of Oncolytics Biotech is held by institutions.

  • Read more about Oncolytics Biotech's insider trading history.
Receive ONCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

ONCY Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

ONCY Stock Analysis - Frequently Asked Questions

Oncolytics Biotech's stock was trading at $0.9138 at the beginning of the year. Since then, ONCY stock has decreased by 1.4% and is now trading at $0.9010.

Oncolytics Biotech Inc. (NASDAQ:ONCY) announced its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.03.
Read the conference call transcript
.

Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), Meta Platforms (META), QUALCOMM (QCOM) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
5/14/2025
Today
7/05/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ONCY
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.33
High Stock Price Target
$5.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+380.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$23.14 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.05 per share
Price / Book
18.02

Miscellaneous

Free Float
94,190,000
Market Cap
$84.95 million
Optionable
Not Optionable
Beta
1.07
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ONCY) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners